SlideShare a Scribd company logo
Polyherbal Formulations for Diabetes
Prof. Dr. Basavaraj K. Nanjwade. M.Pharm., Ph.D.
Department of Pharmaceutics
KLE University College of Pharmacy
Belgaum, Karnataka , India
E-mail: bknanjwade@yahoo.co.in
Cell No: 00919742431000
Graphical Abstract
7 September 2011 14th ACC and ANRAP, Bangkok 2
Introduction
• Plant formulation and combined extracts of plants are used a
drug of choice rather than individual. Various herbal
formulations such as diamed, coagent db, Diasulin, and
hyponidd, are well known for their antidiabetic effects.
• Polyherbal formulation of Annona squamosa and Nigella
sativa is composed of medicinal plants (Table 1), which are
traditionally used for antidiabetic and antihyperlipidemic
activity. The present investigation was undertaken to study the
effect of the polyherbal formulation of Annona sqamosa and
Nigella sativa on lipidperoxidation and tissue lipid profile in
streptozotocin induced diabetic rats.
7 September 2011 14th ACC and ANRAP, Bangkok 3
Research Background
• Polyherbal formulation of Annona squamosa and Nigella
sativa on blood glucose, plasma insulin, tissue lipid profile,
and lipidperoxidation in streptozotocin induced diabetic rats.
Aqueous extract of Polyherbal formulation of Annona
squamosa and Nigella sativa was administered orally (200
mg/kg body weight) for 30 days.
• The different doses of Polyherbal formulation on blood
glucose and plasma insulin in diabetic rats were studied and
the levels of lipid peroxides and tissue lipids were also
estimated in streptozotocin induced diabetic rats. The effects
were compared with tolbutamide. Treatment with Polyherbal
formulation and tolbutamide resulted in a significant reduction
of blood glucose and increase in plasma insulin.
7 September 2011 14th ACC and ANRAP, Bangkok 4
Annona squamosa (Sugar–Apple)
7 September 2011 14th ACC and ANRAP, Bangkok 5
Nigella sativa
7 September 2011 14th ACC and ANRAP, Bangkok 6
Material and methods
• Animals
• Preparation of drug
• Chemicals
• Drug administration
• Streptozotocin-induced diabetes
• Experimental design
• Biochemical analysis
7 September 2011 14th ACC and ANRAP, Bangkok 7
Experimental design
• In the experiment, a total of 42 rats (30
diabetic surviving rats, 12 normal rats)
were used.
• The rats were divided into seven groups of
six rats each after the induction of
streptozotocin diabetes.
7 September 2011 14th ACC and ANRAP, Bangkok 8
Experimental design
• Group1: Normal treated rats
• Group 2:Normal rats given aqueous solution of Polyherbal
formulation (200 mg/kg body weight) daily using an
intragastric tube for 30 days.
• Group 3:Diabetic control rats.
• Group 4: Diabetic rats given aqueous solution of Polyherbal
formulation (50 mg/kg body weight) daily using an
intragastric tube for 30 days.
7 September 2011 14th ACC and ANRAP, Bangkok 9
Experimental design
• Group 5: Diabetic rats given aqueous solution of Polyherbal
formulation (100 mg/kg body weight) daily using an
intragastric tube for 30 days.
• Group 6: Diabetic rats given aqueous solution of Polyherbal
formulation (200 mg/kg body weight) daily using an
intragastric tube for 30 days.
• Group 7: Diabetic rats given aqueous solution of Tolbutamide
(250 mg/kg body weight) daily using an intragastric tube for
30 days.
7 September 2011 14th ACC and ANRAP, Bangkok 10
Biochemical analysis
• Estimation of blood glucose and plasma insulin
• Estimation of lipid peroxidation
• Estimation of lipids
i. Lipids
ii. For total cholesterol estimation
iii. Fro triglycerides estimation
iv. Phopholipids content
v. Free fatty acids
vi. Statistical analysis
7 September 2011 14th ACC and ANRAP, Bangkok 11
Table 1: Polyherbal Formulation of Annona Squamosa and
Nigella sativa (Composition and Concentration)
Sl. No Botanical Name Common
Name
Family Part
used
Conc.
1. Annona
squamosa
Sharifa Annonnacceae Mature
d fruits
50
2. Nigella sative Kalonji Ranunculaceae seeds 50
7 September 2011 14th ACC and ANRAP, Bangkok 12
Group Fasting blood glucose
(mg/dI)
Plasma insulin (IU/ml)
Normal 81.04 ± 2.29 11.26 ± 0.96
Diabetic control 262.24 ± 22.23 3.48 ± 0.69
Diabetic + Polyherbal
formulation (50 mg/kg)
209.58 ± 12.46 5.59 ± 0.34
Diabetic + Polyherbal
formulation (100 mg/kg)
155.58 ± 11.69 6.03 ± 0.45
Diabetic + Polyherbal
formulation (200 mg/kg)
104.16 ± 6.56 7.15 ± 0.45
Diabetic + Tolbutamide
(250 mg/kg)
110.65 ± 9.35 6.32 ± 0.48
7 September 2011 14th ACC and ANRAP, Bangkok 13
Table 2: Changes in blood glucose and plasma insulin
levels of control and experimental animals
Groups TBARS Hydroperoxide
Liver Kidney Liver Kidney
Normal 0.58 ± 0.066 0.68 ± 0.05 70.38 ± 4.54 55.34 ± 4.55
Diabetic +
Polyherbal
formulation
(200 mg/kg)
0.56 ± 0.079 0.78 ± 0.06 68.59 ± 5.14 52.48 ± 4.75
Diabetic
control
1.54 ± 0.06 1.65 ± 0.12 99.98 ± 5.98 78.29 ± 4.58
Diabetic +
Polyherbal
formulation
(200 mg/kg)
0.64 ± 0.053 0.97 ± 0.07 80.55 ± 5.69 60.99 ± 4.78
Diabetic +
Tolbutamide
(250 mg/kg)
0.67 ± 0.088 1.02 ± 0.08 84.35 ± 5.45 62.45 ± 5.56
7 September 2011 14th ACC and ANRAP, Bangkok 14
Table 3: Changes in levels of TBARS and Hydroperoxides
in liver and kidney of control and experimental animals
Table 4: Changes in levels of cholestrol, free fatty acids, triglycerides
and phospholipids in liver of control and experimental animals
( mg/100g wet. tissue)
Groups Cholesterol Free fatty acids Triglycerides Phospholipids
Normal 335.44 ± 18.90 606.10 ± 1.76 344.50 ± 23.20 1598.00 ± 19.30
Normal +
Polyherbal
formulation
(200 mg/kg)
328.38 ± 5.74 601.93 ± 9.00 341.10 ± 21.00 1593.10 ± 24.10
Diabetic control 496.56 ± 13.10 921.60 ± 44.60 622.50 ± 18.80 1858.60 ± 18.70
Diabetic +
Polyherbal
formulation
(200mg/kg)
398.65 ± 17.54 769.16 ± 3.30 456.25 ± 17.30 1718.80 ± 14.40
Diabetic +
Tolbutamide
(250 mg/kg)
405.21 ± 9.79 802.80 ± 3.77 530.80 ± 35.70 1769.30 ± 17.60
7 September 2011 14th ACC and ANRAP, Bangkok 15
Groups Cholesterol Free fatty acids Triglycerides Phospholopids
Normal +
Polyherbal
formulation
(200 mg/kg)
372.08±8.28 432.51±1.60 278.75±14.60 1442.50±43.30
Diabetic control 546.90±23.80 743.00±5.70 501.10±34.10 2041.50±33.60
Diabetic+Polyher
bal formulation
(200 mg/kg)
435.20±12.18 556.80±8.50 382.90±9.28 1684.00±28.80
Diabetic+
Tolbutamide
(250 mg/kg)
449.90±13.49 600.30±3.40 438.66±39.30 1819.30±34.70
7 September 2011 14th ACC and ANRAP, Bangkok 16
Table 5: Changes in levels of cholestrol, free fatty acids, triglycerides
and phospholipids in kidney of control and experimental animals
( mg/100g wet. tissue)
Conclusion
• Polyherbal formulation of Annona squamosa and
Nigella sativa, exert a significant antihyperlipidemic.
This could be due to combined effect of Annona
squamosa and Nigella sativa. Hence the
antihyperlipidemic effect of polyherbal formulation
of Annona squamosa and Nigella sativa in particular
could be considered as of possible therapeutic value
7 September 2011 14th ACC and ANRAP, Bangkok 17
Liposomes
7 September 2011 14th ACC and ANRAP, Bangkok 18
– Spherical vesicles with a phospholipid bilayer
Hydrophilic
HydrophobicHydrophobic
7 September 2011 14th ACC and ANRAP, Bangkok 19
Liposome Preparation
7 September 2011 14th ACC and ANRAP, Bangkok 20
Liposome Preparation
7 September 2011 14th ACC and ANRAP, Bangkok 21
Liposome Preparation
7 September 2011 14th ACC and ANRAP, Bangkok 22
Lipid Peroxidation
• Most phospholipid liposomes contain
unsaturated acyl chains as part of their
molecular structure and susceptible to
oxidative degradation. It can be minimized by
the use of animal derived lipids like egg PC,
which has less saturated lipids, use of light
resistant containers, use of antioxidants are
useful in minimizing oxidation.
7 September 2011 14th ACC and ANRAP, Bangkok 23
Diabetic Current Research
• Mangifera indica(stem,fruits,etc) – Anacardiaceae – Mango
• Gossypiumherbaceum(flowers,etc ) – Malvaceae – Cotton
• Cocos nucifera(roots,etc) – Arecaceae – Coconut
• Lawsonia inermis(bark,etc) – Lythraceae - Mendhi
7 September 2011 2414th ACC and ANRAP, Bangkok
My Research Group
7 September 2011 14th ACC and ANRAP, Bangkok 25
THANK YOUE-mail: bknanjwade@yahoo.co.in
Cell No: 0091 9742431000
7 September 2011 14th ACC and ANRAP, Bangkok 26

More Related Content

What's hot

Polyherbal formulation development for anti asthmatic activity
Polyherbal formulation development for anti asthmatic activityPolyherbal formulation development for anti asthmatic activity
Polyherbal formulation development for anti asthmatic activity
pharmaindexing
 
WHO guidelines for quality control of herbal drugs
WHO guidelines for quality control of herbal drugsWHO guidelines for quality control of herbal drugs
WHO guidelines for quality control of herbal drugs
Dr. Siddhi Upadhyay
 
Tablet types and Excipients
Tablet  types and ExcipientsTablet  types and Excipients
Tablet types and Excipients
Komal Haleem
 
Tablet manufacturing process
Tablet manufacturing processTablet manufacturing process
Tablet manufacturing process
Avinash Gowda
 
Comparison of herbal pharmacopoeias
Comparison of herbal pharmacopoeiasComparison of herbal pharmacopoeias
Comparison of herbal pharmacopoeias
Dr-Jitendra Patel
 
Bio pharmaceutical classification System [BCS]
Bio pharmaceutical classification System [BCS]Bio pharmaceutical classification System [BCS]
Bio pharmaceutical classification System [BCS]
Sagar Savale
 
Novel drug delivery system based herbal formulations
Novel drug delivery system based herbal formulationsNovel drug delivery system based herbal formulations
Novel drug delivery system based herbal formulationsNitin Patel
 
Herb drug interaction
Herb drug interactionHerb drug interaction
Herb drug interaction
Vandana Janghel
 
Granulation ppt
Granulation pptGranulation ppt
Granulation ppt
SAJJAD AHMAD
 
Clove
CloveClove
Dissolution Testing Apparatus
Dissolution Testing ApparatusDissolution Testing Apparatus
Dissolution Testing Apparatus
Sourav Kar
 
Single punch tablet press PPT
Single punch tablet press PPTSingle punch tablet press PPT
Single punch tablet press PPT
pharmastuffblogspotcom
 
BCS classification system : Applications in pharmaceutics
BCS classification system : Applications in pharmaceutics BCS classification system : Applications in pharmaceutics
BCS classification system : Applications in pharmaceutics
Hemant Khandoliya
 
Cyclodextrin
Cyclodextrin Cyclodextrin
Cyclodextrin
Ritesh Ghate
 
Herbal Cosmetics
Herbal CosmeticsHerbal Cosmetics
Herbal Cosmetics
Dr. Siddhi Upadhyay
 
Quality control tests of tablet
Quality control tests of tabletQuality control tests of tablet
Quality control tests of tablet
SarangDalvi
 
Spectroscopy in pharmacognosy
Spectroscopy in pharmacognosySpectroscopy in pharmacognosy
Spectroscopy in pharmacognosy
SurbhiSharma196
 
Tablets formulation
Tablets formulationTablets formulation
Tablets formulation
Arantha Jessy Joseph
 
pharmacy Industrial training report
pharmacy Industrial training reportpharmacy Industrial training report
pharmacy Industrial training report
Gaurav Patil
 

What's hot (20)

Polyherbal formulation development for anti asthmatic activity
Polyherbal formulation development for anti asthmatic activityPolyherbal formulation development for anti asthmatic activity
Polyherbal formulation development for anti asthmatic activity
 
WHO guidelines for quality control of herbal drugs
WHO guidelines for quality control of herbal drugsWHO guidelines for quality control of herbal drugs
WHO guidelines for quality control of herbal drugs
 
Tablet types and Excipients
Tablet  types and ExcipientsTablet  types and Excipients
Tablet types and Excipients
 
Tablet manufacturing process
Tablet manufacturing processTablet manufacturing process
Tablet manufacturing process
 
Comparison of herbal pharmacopoeias
Comparison of herbal pharmacopoeiasComparison of herbal pharmacopoeias
Comparison of herbal pharmacopoeias
 
Bio pharmaceutical classification System [BCS]
Bio pharmaceutical classification System [BCS]Bio pharmaceutical classification System [BCS]
Bio pharmaceutical classification System [BCS]
 
Novel drug delivery system based herbal formulations
Novel drug delivery system based herbal formulationsNovel drug delivery system based herbal formulations
Novel drug delivery system based herbal formulations
 
Herb drug interaction
Herb drug interactionHerb drug interaction
Herb drug interaction
 
Granulation ppt
Granulation pptGranulation ppt
Granulation ppt
 
Clove
CloveClove
Clove
 
Dissolution Testing Apparatus
Dissolution Testing ApparatusDissolution Testing Apparatus
Dissolution Testing Apparatus
 
Single punch tablet press PPT
Single punch tablet press PPTSingle punch tablet press PPT
Single punch tablet press PPT
 
BCS classification system : Applications in pharmaceutics
BCS classification system : Applications in pharmaceutics BCS classification system : Applications in pharmaceutics
BCS classification system : Applications in pharmaceutics
 
Cyclodextrin
Cyclodextrin Cyclodextrin
Cyclodextrin
 
Herbal Cosmetics
Herbal CosmeticsHerbal Cosmetics
Herbal Cosmetics
 
preformulation
preformulationpreformulation
preformulation
 
Quality control tests of tablet
Quality control tests of tabletQuality control tests of tablet
Quality control tests of tablet
 
Spectroscopy in pharmacognosy
Spectroscopy in pharmacognosySpectroscopy in pharmacognosy
Spectroscopy in pharmacognosy
 
Tablets formulation
Tablets formulationTablets formulation
Tablets formulation
 
pharmacy Industrial training report
pharmacy Industrial training reportpharmacy Industrial training report
pharmacy Industrial training report
 

Similar to Polyherbal formulations for diabetic

Drug discovery and development process of anti diabetic plants
Drug discovery and development process of anti diabetic plantsDrug discovery and development process of anti diabetic plants
Drug discovery and development process of anti diabetic plants
Prof. Dr. Basavaraj Nanjwade
 
Macrocarpa antidiabetic
Macrocarpa antidiabeticMacrocarpa antidiabetic
Macrocarpa antidiabetic
PrabhatJha74
 
Effect of ethanolic extract of piper cubeba linn fruits on activity of piogli...
Effect of ethanolic extract of piper cubeba linn fruits on activity of piogli...Effect of ethanolic extract of piper cubeba linn fruits on activity of piogli...
Effect of ethanolic extract of piper cubeba linn fruits on activity of piogli...
srirampharma
 
CASE STUDY 1 (Q2)
 CASE STUDY 1 (Q2) CASE STUDY 1 (Q2)
CASE STUDY 1 (Q2)Wan Hazirah
 
Succeed Cestaro Presentation 031209
Succeed Cestaro Presentation 031209Succeed Cestaro Presentation 031209
Succeed Cestaro Presentation 031209
steiner881
 
Effect of Piper crocatum Extract Against Weight Loss and Liver Enzyme Levels ...
Effect of Piper crocatum Extract Against Weight Loss and Liver Enzyme Levels ...Effect of Piper crocatum Extract Against Weight Loss and Liver Enzyme Levels ...
Effect of Piper crocatum Extract Against Weight Loss and Liver Enzyme Levels ...
iosrphr_editor
 
Baliospermum montanum roots
Baliospermum montanum rootsBaliospermum montanum roots
Baliospermum montanum roots
pharmaindexing
 
Thesis presentation of sumaiya nahid
Thesis presentation of sumaiya nahidThesis presentation of sumaiya nahid
Thesis presentation of sumaiya nahid
sumaiya nahid
 
Potential mechanisms underlying the yogurt-body weight relationship
Potential mechanisms underlying the yogurt-body weight relationshipPotential mechanisms underlying the yogurt-body weight relationship
Potential mechanisms underlying the yogurt-body weight relationship
Yogurt in Nutrition #YINI
 
alphaglucosidase inhibitors
alphaglucosidase inhibitorsalphaglucosidase inhibitors
alphaglucosidase inhibitors
VineetSaboo2
 
alpha glucosidase inhibitor
alpha glucosidase inhibitoralpha glucosidase inhibitor
alpha glucosidase inhibitor
SabooDiabetesCentre
 
Gluconarc (ayu dia) irp 002
Gluconarc (ayu dia) irp 002Gluconarc (ayu dia) irp 002
Gluconarc (ayu dia) irp 002
Dr.Shivalinge Gowda KP
 
IOSR Journal of Pharmacy (IOSRPHR), www.iosrphr.org, call for paper, research...
IOSR Journal of Pharmacy (IOSRPHR), www.iosrphr.org, call for paper, research...IOSR Journal of Pharmacy (IOSRPHR), www.iosrphr.org, call for paper, research...
IOSR Journal of Pharmacy (IOSRPHR), www.iosrphr.org, call for paper, research...iosrphr_editor
 
DIVYA THEIS PPT.pptx
DIVYA THEIS PPT.pptxDIVYA THEIS PPT.pptx
DIVYA THEIS PPT.pptx
DIVYAKALE14
 
Screening of DHB against Hepatorenal toxicity.
Screening of DHB against Hepatorenal toxicity.Screening of DHB against Hepatorenal toxicity.
Screening of DHB against Hepatorenal toxicity.
Gulshan Athbhaiya
 
Asrt malaysia itm rice bran projects presentation
Asrt   malaysia  itm rice bran  projects presentationAsrt   malaysia  itm rice bran  projects presentation
Asrt malaysia itm rice bran projects presentation
Amr Helal
 
Kidneydisease case study
Kidneydisease case studyKidneydisease case study
Kidneydisease case studyMarissa Uhlhorn
 

Similar to Polyherbal formulations for diabetic (20)

Drug discovery and development process of anti diabetic plants
Drug discovery and development process of anti diabetic plantsDrug discovery and development process of anti diabetic plants
Drug discovery and development process of anti diabetic plants
 
Macrocarpa antidiabetic
Macrocarpa antidiabeticMacrocarpa antidiabetic
Macrocarpa antidiabetic
 
Effect of ethanolic extract of piper cubeba linn fruits on activity of piogli...
Effect of ethanolic extract of piper cubeba linn fruits on activity of piogli...Effect of ethanolic extract of piper cubeba linn fruits on activity of piogli...
Effect of ethanolic extract of piper cubeba linn fruits on activity of piogli...
 
CASE STUDY 1 (Q2)
 CASE STUDY 1 (Q2) CASE STUDY 1 (Q2)
CASE STUDY 1 (Q2)
 
Succeed Cestaro Presentation 031209
Succeed Cestaro Presentation 031209Succeed Cestaro Presentation 031209
Succeed Cestaro Presentation 031209
 
Effect of Piper crocatum Extract Against Weight Loss and Liver Enzyme Levels ...
Effect of Piper crocatum Extract Against Weight Loss and Liver Enzyme Levels ...Effect of Piper crocatum Extract Against Weight Loss and Liver Enzyme Levels ...
Effect of Piper crocatum Extract Against Weight Loss and Liver Enzyme Levels ...
 
Baliospermum montanum roots
Baliospermum montanum rootsBaliospermum montanum roots
Baliospermum montanum roots
 
1402-5031-2-PB
1402-5031-2-PB1402-5031-2-PB
1402-5031-2-PB
 
Thesis presentation of sumaiya nahid
Thesis presentation of sumaiya nahidThesis presentation of sumaiya nahid
Thesis presentation of sumaiya nahid
 
Potential mechanisms underlying the yogurt-body weight relationship
Potential mechanisms underlying the yogurt-body weight relationshipPotential mechanisms underlying the yogurt-body weight relationship
Potential mechanisms underlying the yogurt-body weight relationship
 
495926
495926495926
495926
 
Femi's seminar2
Femi's seminar2Femi's seminar2
Femi's seminar2
 
alphaglucosidase inhibitors
alphaglucosidase inhibitorsalphaglucosidase inhibitors
alphaglucosidase inhibitors
 
alpha glucosidase inhibitor
alpha glucosidase inhibitoralpha glucosidase inhibitor
alpha glucosidase inhibitor
 
Gluconarc (ayu dia) irp 002
Gluconarc (ayu dia) irp 002Gluconarc (ayu dia) irp 002
Gluconarc (ayu dia) irp 002
 
IOSR Journal of Pharmacy (IOSRPHR), www.iosrphr.org, call for paper, research...
IOSR Journal of Pharmacy (IOSRPHR), www.iosrphr.org, call for paper, research...IOSR Journal of Pharmacy (IOSRPHR), www.iosrphr.org, call for paper, research...
IOSR Journal of Pharmacy (IOSRPHR), www.iosrphr.org, call for paper, research...
 
DIVYA THEIS PPT.pptx
DIVYA THEIS PPT.pptxDIVYA THEIS PPT.pptx
DIVYA THEIS PPT.pptx
 
Screening of DHB against Hepatorenal toxicity.
Screening of DHB against Hepatorenal toxicity.Screening of DHB against Hepatorenal toxicity.
Screening of DHB against Hepatorenal toxicity.
 
Asrt malaysia itm rice bran projects presentation
Asrt   malaysia  itm rice bran  projects presentationAsrt   malaysia  itm rice bran  projects presentation
Asrt malaysia itm rice bran projects presentation
 
Kidneydisease case study
Kidneydisease case studyKidneydisease case study
Kidneydisease case study
 

More from Prof. Dr. Basavaraj Nanjwade

Injectable, Ophthalmic, Controlled-Release Solid Orals Considering Regulator...
Injectable,  Ophthalmic, Controlled-Release Solid Orals Considering Regulator...Injectable,  Ophthalmic, Controlled-Release Solid Orals Considering Regulator...
Injectable, Ophthalmic, Controlled-Release Solid Orals Considering Regulator...
Prof. Dr. Basavaraj Nanjwade
 
Current and Future Aspects of AI In Drug Discovery Design and Development.pptx
Current and Future  Aspects of AI In Drug Discovery  Design and Development.pptxCurrent and Future  Aspects of AI In Drug Discovery  Design and Development.pptx
Current and Future Aspects of AI In Drug Discovery Design and Development.pptx
Prof. Dr. Basavaraj Nanjwade
 
COVID-19 and Novel Drug Delivery System.ppt
COVID-19 and Novel Drug Delivery System.pptCOVID-19 and Novel Drug Delivery System.ppt
COVID-19 and Novel Drug Delivery System.ppt
Prof. Dr. Basavaraj Nanjwade
 
Good laboratory practices for pharmaceuticals and biopharmaceuticals
Good laboratory practices for pharmaceuticals  and  biopharmaceuticalsGood laboratory practices for pharmaceuticals  and  biopharmaceuticals
Good laboratory practices for pharmaceuticals and biopharmaceuticals
Prof. Dr. Basavaraj Nanjwade
 
Opportunities and future for pharmacist
Opportunities and future for pharmacistOpportunities and future for pharmacist
Opportunities and future for pharmacist
Prof. Dr. Basavaraj Nanjwade
 
Opportunities and future for pharmacist
Opportunities and future for pharmacistOpportunities and future for pharmacist
Opportunities and future for pharmacist
Prof. Dr. Basavaraj Nanjwade
 
Novel drug delivery system
Novel drug delivery systemNovel drug delivery system
Novel drug delivery system
Prof. Dr. Basavaraj Nanjwade
 
Packaging and Stability Requirements for Pharmaceuticals
Packaging and Stability Requirements for PharmaceuticalsPackaging and Stability Requirements for Pharmaceuticals
Packaging and Stability Requirements for Pharmaceuticals
Prof. Dr. Basavaraj Nanjwade
 
QbD for Product Development of Solid Semisolid and Liquid Dosage Forms
QbD for Product Development of Solid Semisolid and Liquid Dosage FormsQbD for Product Development of Solid Semisolid and Liquid Dosage Forms
QbD for Product Development of Solid Semisolid and Liquid Dosage Forms
Prof. Dr. Basavaraj Nanjwade
 
Opportunities and Future for Pharma Buddies
Opportunities and Future for Pharma BuddiesOpportunities and Future for Pharma Buddies
Opportunities and Future for Pharma Buddies
Prof. Dr. Basavaraj Nanjwade
 
Development of Clinical Formulation
Development of Clinical FormulationDevelopment of Clinical Formulation
Development of Clinical Formulation
Prof. Dr. Basavaraj Nanjwade
 
QbD for Pharma Products Development
QbD for Pharma Products DevelopmentQbD for Pharma Products Development
QbD for Pharma Products Development
Prof. Dr. Basavaraj Nanjwade
 
Development, safety and stability of biotechnological and biological products
Development, safety and stability of biotechnological and biological productsDevelopment, safety and stability of biotechnological and biological products
Development, safety and stability of biotechnological and biological products
Prof. Dr. Basavaraj Nanjwade
 
Clinical studies and trials on traditional medicine and natural products
Clinical studies and trials on traditional medicine and natural productsClinical studies and trials on traditional medicine and natural products
Clinical studies and trials on traditional medicine and natural products
Prof. Dr. Basavaraj Nanjwade
 
Clinical drug design
Clinical drug designClinical drug design
Clinical drug design
Prof. Dr. Basavaraj Nanjwade
 
Clinical drug development
Clinical drug developmentClinical drug development
Clinical drug development
Prof. Dr. Basavaraj Nanjwade
 
Clinical drug design
Clinical drug designClinical drug design
Clinical drug design
Prof. Dr. Basavaraj Nanjwade
 
Solid dosage forms (tablets)
Solid dosage forms (tablets)Solid dosage forms (tablets)
Solid dosage forms (tablets)
Prof. Dr. Basavaraj Nanjwade
 
Solid dosage forms (capsules)
Solid dosage forms (capsules)Solid dosage forms (capsules)
Solid dosage forms (capsules)
Prof. Dr. Basavaraj Nanjwade
 
Preparations in pharmacy of hospital
Preparations in pharmacy of hospitalPreparations in pharmacy of hospital
Preparations in pharmacy of hospital
Prof. Dr. Basavaraj Nanjwade
 

More from Prof. Dr. Basavaraj Nanjwade (20)

Injectable, Ophthalmic, Controlled-Release Solid Orals Considering Regulator...
Injectable,  Ophthalmic, Controlled-Release Solid Orals Considering Regulator...Injectable,  Ophthalmic, Controlled-Release Solid Orals Considering Regulator...
Injectable, Ophthalmic, Controlled-Release Solid Orals Considering Regulator...
 
Current and Future Aspects of AI In Drug Discovery Design and Development.pptx
Current and Future  Aspects of AI In Drug Discovery  Design and Development.pptxCurrent and Future  Aspects of AI In Drug Discovery  Design and Development.pptx
Current and Future Aspects of AI In Drug Discovery Design and Development.pptx
 
COVID-19 and Novel Drug Delivery System.ppt
COVID-19 and Novel Drug Delivery System.pptCOVID-19 and Novel Drug Delivery System.ppt
COVID-19 and Novel Drug Delivery System.ppt
 
Good laboratory practices for pharmaceuticals and biopharmaceuticals
Good laboratory practices for pharmaceuticals  and  biopharmaceuticalsGood laboratory practices for pharmaceuticals  and  biopharmaceuticals
Good laboratory practices for pharmaceuticals and biopharmaceuticals
 
Opportunities and future for pharmacist
Opportunities and future for pharmacistOpportunities and future for pharmacist
Opportunities and future for pharmacist
 
Opportunities and future for pharmacist
Opportunities and future for pharmacistOpportunities and future for pharmacist
Opportunities and future for pharmacist
 
Novel drug delivery system
Novel drug delivery systemNovel drug delivery system
Novel drug delivery system
 
Packaging and Stability Requirements for Pharmaceuticals
Packaging and Stability Requirements for PharmaceuticalsPackaging and Stability Requirements for Pharmaceuticals
Packaging and Stability Requirements for Pharmaceuticals
 
QbD for Product Development of Solid Semisolid and Liquid Dosage Forms
QbD for Product Development of Solid Semisolid and Liquid Dosage FormsQbD for Product Development of Solid Semisolid and Liquid Dosage Forms
QbD for Product Development of Solid Semisolid and Liquid Dosage Forms
 
Opportunities and Future for Pharma Buddies
Opportunities and Future for Pharma BuddiesOpportunities and Future for Pharma Buddies
Opportunities and Future for Pharma Buddies
 
Development of Clinical Formulation
Development of Clinical FormulationDevelopment of Clinical Formulation
Development of Clinical Formulation
 
QbD for Pharma Products Development
QbD for Pharma Products DevelopmentQbD for Pharma Products Development
QbD for Pharma Products Development
 
Development, safety and stability of biotechnological and biological products
Development, safety and stability of biotechnological and biological productsDevelopment, safety and stability of biotechnological and biological products
Development, safety and stability of biotechnological and biological products
 
Clinical studies and trials on traditional medicine and natural products
Clinical studies and trials on traditional medicine and natural productsClinical studies and trials on traditional medicine and natural products
Clinical studies and trials on traditional medicine and natural products
 
Clinical drug design
Clinical drug designClinical drug design
Clinical drug design
 
Clinical drug development
Clinical drug developmentClinical drug development
Clinical drug development
 
Clinical drug design
Clinical drug designClinical drug design
Clinical drug design
 
Solid dosage forms (tablets)
Solid dosage forms (tablets)Solid dosage forms (tablets)
Solid dosage forms (tablets)
 
Solid dosage forms (capsules)
Solid dosage forms (capsules)Solid dosage forms (capsules)
Solid dosage forms (capsules)
 
Preparations in pharmacy of hospital
Preparations in pharmacy of hospitalPreparations in pharmacy of hospital
Preparations in pharmacy of hospital
 

Recently uploaded

Radiation Oncology Market PPT: Growth, Outlook, Demand, Keyplayer Analysis an...
Radiation Oncology Market PPT: Growth, Outlook, Demand, Keyplayer Analysis an...Radiation Oncology Market PPT: Growth, Outlook, Demand, Keyplayer Analysis an...
Radiation Oncology Market PPT: Growth, Outlook, Demand, Keyplayer Analysis an...
IMARC Group
 
KEY Points of Leicester travel clinic In London doc.docx
KEY Points of Leicester travel clinic In London doc.docxKEY Points of Leicester travel clinic In London doc.docx
KEY Points of Leicester travel clinic In London doc.docx
NX Healthcare
 
Suraj Goswami Journey From Guru Kashi University
Suraj Goswami Journey From Guru Kashi UniversitySuraj Goswami Journey From Guru Kashi University
Suraj Goswami Journey From Guru Kashi University
Suraj Goswami
 
Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...
Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...
Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...
The Lifesciences Magazine
 
The Impact of Meeting: How It Can Change Your Life
The Impact of Meeting: How It Can Change Your LifeThe Impact of Meeting: How It Can Change Your Life
The Impact of Meeting: How It Can Change Your Life
ranishasharma67
 
POLYCYSTIC OVARIAN SYNDROME (PCOS)......
POLYCYSTIC OVARIAN SYNDROME (PCOS)......POLYCYSTIC OVARIAN SYNDROME (PCOS)......
POLYCYSTIC OVARIAN SYNDROME (PCOS)......
Ameena Kadar
 
ventilator, child on ventilator, newborn
ventilator, child on ventilator, newbornventilator, child on ventilator, newborn
ventilator, child on ventilator, newborn
Pooja Rani
 
the IUA Administrative Board and General Assembly meeting
the IUA Administrative Board and General Assembly meetingthe IUA Administrative Board and General Assembly meeting
the IUA Administrative Board and General Assembly meeting
ssuser787e5c1
 
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
ranishasharma67
 
Cardiac Arrhythmias (2).pdf for nursing student
Cardiac Arrhythmias (2).pdf for nursing studentCardiac Arrhythmias (2).pdf for nursing student
Cardiac Arrhythmias (2).pdf for nursing student
fahmyahmed789
 
Navigating Women's Health: Understanding Prenatal Care and Beyond
Navigating Women's Health: Understanding Prenatal Care and BeyondNavigating Women's Health: Understanding Prenatal Care and Beyond
Navigating Women's Health: Understanding Prenatal Care and Beyond
Aboud Health Group
 
Dimensions of Healthcare Quality
Dimensions of Healthcare QualityDimensions of Healthcare Quality
Dimensions of Healthcare Quality
Naeemshahzad51
 
The Importance of COVID-19 PCR Tests for Travel in 2024.pptx
The Importance of COVID-19 PCR Tests for Travel in 2024.pptxThe Importance of COVID-19 PCR Tests for Travel in 2024.pptx
The Importance of COVID-19 PCR Tests for Travel in 2024.pptx
Global Travel Clinics
 
DRAFT Ventilator Rapid Reference version 2.4.pdf
DRAFT Ventilator Rapid Reference  version  2.4.pdfDRAFT Ventilator Rapid Reference  version  2.4.pdf
DRAFT Ventilator Rapid Reference version 2.4.pdf
Robert Cole
 
One Gene One Enzyme Theory.pptxvhvhfhfhfhf
One Gene One Enzyme Theory.pptxvhvhfhfhfhfOne Gene One Enzyme Theory.pptxvhvhfhfhfhf
One Gene One Enzyme Theory.pptxvhvhfhfhfhf
AbdulMunim54
 
HEAT WAVE presented by priya bhojwani..pptx
HEAT WAVE presented by priya bhojwani..pptxHEAT WAVE presented by priya bhojwani..pptx
HEAT WAVE presented by priya bhojwani..pptx
priyabhojwani1200
 
Letter to MREC - application to conduct study
Letter to MREC - application to conduct studyLetter to MREC - application to conduct study
Letter to MREC - application to conduct study
Azreen Aj
 
Child Welfare Clinic and Well baby clinicin Sri Lanka.ppsx
Child Welfare Clinic and Well baby clinicin Sri Lanka.ppsxChild Welfare Clinic and Well baby clinicin Sri Lanka.ppsx
Child Welfare Clinic and Well baby clinicin Sri Lanka.ppsx
Sankalpa Gunathilaka
 
karnapuran PPT made by Dr nishant very easy to understand how karanapuran is ...
karnapuran PPT made by Dr nishant very easy to understand how karanapuran is ...karnapuran PPT made by Dr nishant very easy to understand how karanapuran is ...
karnapuran PPT made by Dr nishant very easy to understand how karanapuran is ...
Nishant Taralkar
 
The Docs PPG - 30.05.2024.pptx..........
The Docs PPG - 30.05.2024.pptx..........The Docs PPG - 30.05.2024.pptx..........
The Docs PPG - 30.05.2024.pptx..........
TheDocs
 

Recently uploaded (20)

Radiation Oncology Market PPT: Growth, Outlook, Demand, Keyplayer Analysis an...
Radiation Oncology Market PPT: Growth, Outlook, Demand, Keyplayer Analysis an...Radiation Oncology Market PPT: Growth, Outlook, Demand, Keyplayer Analysis an...
Radiation Oncology Market PPT: Growth, Outlook, Demand, Keyplayer Analysis an...
 
KEY Points of Leicester travel clinic In London doc.docx
KEY Points of Leicester travel clinic In London doc.docxKEY Points of Leicester travel clinic In London doc.docx
KEY Points of Leicester travel clinic In London doc.docx
 
Suraj Goswami Journey From Guru Kashi University
Suraj Goswami Journey From Guru Kashi UniversitySuraj Goswami Journey From Guru Kashi University
Suraj Goswami Journey From Guru Kashi University
 
Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...
Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...
Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...
 
The Impact of Meeting: How It Can Change Your Life
The Impact of Meeting: How It Can Change Your LifeThe Impact of Meeting: How It Can Change Your Life
The Impact of Meeting: How It Can Change Your Life
 
POLYCYSTIC OVARIAN SYNDROME (PCOS)......
POLYCYSTIC OVARIAN SYNDROME (PCOS)......POLYCYSTIC OVARIAN SYNDROME (PCOS)......
POLYCYSTIC OVARIAN SYNDROME (PCOS)......
 
ventilator, child on ventilator, newborn
ventilator, child on ventilator, newbornventilator, child on ventilator, newborn
ventilator, child on ventilator, newborn
 
the IUA Administrative Board and General Assembly meeting
the IUA Administrative Board and General Assembly meetingthe IUA Administrative Board and General Assembly meeting
the IUA Administrative Board and General Assembly meeting
 
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
 
Cardiac Arrhythmias (2).pdf for nursing student
Cardiac Arrhythmias (2).pdf for nursing studentCardiac Arrhythmias (2).pdf for nursing student
Cardiac Arrhythmias (2).pdf for nursing student
 
Navigating Women's Health: Understanding Prenatal Care and Beyond
Navigating Women's Health: Understanding Prenatal Care and BeyondNavigating Women's Health: Understanding Prenatal Care and Beyond
Navigating Women's Health: Understanding Prenatal Care and Beyond
 
Dimensions of Healthcare Quality
Dimensions of Healthcare QualityDimensions of Healthcare Quality
Dimensions of Healthcare Quality
 
The Importance of COVID-19 PCR Tests for Travel in 2024.pptx
The Importance of COVID-19 PCR Tests for Travel in 2024.pptxThe Importance of COVID-19 PCR Tests for Travel in 2024.pptx
The Importance of COVID-19 PCR Tests for Travel in 2024.pptx
 
DRAFT Ventilator Rapid Reference version 2.4.pdf
DRAFT Ventilator Rapid Reference  version  2.4.pdfDRAFT Ventilator Rapid Reference  version  2.4.pdf
DRAFT Ventilator Rapid Reference version 2.4.pdf
 
One Gene One Enzyme Theory.pptxvhvhfhfhfhf
One Gene One Enzyme Theory.pptxvhvhfhfhfhfOne Gene One Enzyme Theory.pptxvhvhfhfhfhf
One Gene One Enzyme Theory.pptxvhvhfhfhfhf
 
HEAT WAVE presented by priya bhojwani..pptx
HEAT WAVE presented by priya bhojwani..pptxHEAT WAVE presented by priya bhojwani..pptx
HEAT WAVE presented by priya bhojwani..pptx
 
Letter to MREC - application to conduct study
Letter to MREC - application to conduct studyLetter to MREC - application to conduct study
Letter to MREC - application to conduct study
 
Child Welfare Clinic and Well baby clinicin Sri Lanka.ppsx
Child Welfare Clinic and Well baby clinicin Sri Lanka.ppsxChild Welfare Clinic and Well baby clinicin Sri Lanka.ppsx
Child Welfare Clinic and Well baby clinicin Sri Lanka.ppsx
 
karnapuran PPT made by Dr nishant very easy to understand how karanapuran is ...
karnapuran PPT made by Dr nishant very easy to understand how karanapuran is ...karnapuran PPT made by Dr nishant very easy to understand how karanapuran is ...
karnapuran PPT made by Dr nishant very easy to understand how karanapuran is ...
 
The Docs PPG - 30.05.2024.pptx..........
The Docs PPG - 30.05.2024.pptx..........The Docs PPG - 30.05.2024.pptx..........
The Docs PPG - 30.05.2024.pptx..........
 

Polyherbal formulations for diabetic

  • 1. Polyherbal Formulations for Diabetes Prof. Dr. Basavaraj K. Nanjwade. M.Pharm., Ph.D. Department of Pharmaceutics KLE University College of Pharmacy Belgaum, Karnataka , India E-mail: bknanjwade@yahoo.co.in Cell No: 00919742431000
  • 2. Graphical Abstract 7 September 2011 14th ACC and ANRAP, Bangkok 2
  • 3. Introduction • Plant formulation and combined extracts of plants are used a drug of choice rather than individual. Various herbal formulations such as diamed, coagent db, Diasulin, and hyponidd, are well known for their antidiabetic effects. • Polyherbal formulation of Annona squamosa and Nigella sativa is composed of medicinal plants (Table 1), which are traditionally used for antidiabetic and antihyperlipidemic activity. The present investigation was undertaken to study the effect of the polyherbal formulation of Annona sqamosa and Nigella sativa on lipidperoxidation and tissue lipid profile in streptozotocin induced diabetic rats. 7 September 2011 14th ACC and ANRAP, Bangkok 3
  • 4. Research Background • Polyherbal formulation of Annona squamosa and Nigella sativa on blood glucose, plasma insulin, tissue lipid profile, and lipidperoxidation in streptozotocin induced diabetic rats. Aqueous extract of Polyherbal formulation of Annona squamosa and Nigella sativa was administered orally (200 mg/kg body weight) for 30 days. • The different doses of Polyherbal formulation on blood glucose and plasma insulin in diabetic rats were studied and the levels of lipid peroxides and tissue lipids were also estimated in streptozotocin induced diabetic rats. The effects were compared with tolbutamide. Treatment with Polyherbal formulation and tolbutamide resulted in a significant reduction of blood glucose and increase in plasma insulin. 7 September 2011 14th ACC and ANRAP, Bangkok 4
  • 5. Annona squamosa (Sugar–Apple) 7 September 2011 14th ACC and ANRAP, Bangkok 5
  • 6. Nigella sativa 7 September 2011 14th ACC and ANRAP, Bangkok 6
  • 7. Material and methods • Animals • Preparation of drug • Chemicals • Drug administration • Streptozotocin-induced diabetes • Experimental design • Biochemical analysis 7 September 2011 14th ACC and ANRAP, Bangkok 7
  • 8. Experimental design • In the experiment, a total of 42 rats (30 diabetic surviving rats, 12 normal rats) were used. • The rats were divided into seven groups of six rats each after the induction of streptozotocin diabetes. 7 September 2011 14th ACC and ANRAP, Bangkok 8
  • 9. Experimental design • Group1: Normal treated rats • Group 2:Normal rats given aqueous solution of Polyherbal formulation (200 mg/kg body weight) daily using an intragastric tube for 30 days. • Group 3:Diabetic control rats. • Group 4: Diabetic rats given aqueous solution of Polyherbal formulation (50 mg/kg body weight) daily using an intragastric tube for 30 days. 7 September 2011 14th ACC and ANRAP, Bangkok 9
  • 10. Experimental design • Group 5: Diabetic rats given aqueous solution of Polyherbal formulation (100 mg/kg body weight) daily using an intragastric tube for 30 days. • Group 6: Diabetic rats given aqueous solution of Polyherbal formulation (200 mg/kg body weight) daily using an intragastric tube for 30 days. • Group 7: Diabetic rats given aqueous solution of Tolbutamide (250 mg/kg body weight) daily using an intragastric tube for 30 days. 7 September 2011 14th ACC and ANRAP, Bangkok 10
  • 11. Biochemical analysis • Estimation of blood glucose and plasma insulin • Estimation of lipid peroxidation • Estimation of lipids i. Lipids ii. For total cholesterol estimation iii. Fro triglycerides estimation iv. Phopholipids content v. Free fatty acids vi. Statistical analysis 7 September 2011 14th ACC and ANRAP, Bangkok 11
  • 12. Table 1: Polyherbal Formulation of Annona Squamosa and Nigella sativa (Composition and Concentration) Sl. No Botanical Name Common Name Family Part used Conc. 1. Annona squamosa Sharifa Annonnacceae Mature d fruits 50 2. Nigella sative Kalonji Ranunculaceae seeds 50 7 September 2011 14th ACC and ANRAP, Bangkok 12
  • 13. Group Fasting blood glucose (mg/dI) Plasma insulin (IU/ml) Normal 81.04 ± 2.29 11.26 ± 0.96 Diabetic control 262.24 ± 22.23 3.48 ± 0.69 Diabetic + Polyherbal formulation (50 mg/kg) 209.58 ± 12.46 5.59 ± 0.34 Diabetic + Polyherbal formulation (100 mg/kg) 155.58 ± 11.69 6.03 ± 0.45 Diabetic + Polyherbal formulation (200 mg/kg) 104.16 ± 6.56 7.15 ± 0.45 Diabetic + Tolbutamide (250 mg/kg) 110.65 ± 9.35 6.32 ± 0.48 7 September 2011 14th ACC and ANRAP, Bangkok 13 Table 2: Changes in blood glucose and plasma insulin levels of control and experimental animals
  • 14. Groups TBARS Hydroperoxide Liver Kidney Liver Kidney Normal 0.58 ± 0.066 0.68 ± 0.05 70.38 ± 4.54 55.34 ± 4.55 Diabetic + Polyherbal formulation (200 mg/kg) 0.56 ± 0.079 0.78 ± 0.06 68.59 ± 5.14 52.48 ± 4.75 Diabetic control 1.54 ± 0.06 1.65 ± 0.12 99.98 ± 5.98 78.29 ± 4.58 Diabetic + Polyherbal formulation (200 mg/kg) 0.64 ± 0.053 0.97 ± 0.07 80.55 ± 5.69 60.99 ± 4.78 Diabetic + Tolbutamide (250 mg/kg) 0.67 ± 0.088 1.02 ± 0.08 84.35 ± 5.45 62.45 ± 5.56 7 September 2011 14th ACC and ANRAP, Bangkok 14 Table 3: Changes in levels of TBARS and Hydroperoxides in liver and kidney of control and experimental animals
  • 15. Table 4: Changes in levels of cholestrol, free fatty acids, triglycerides and phospholipids in liver of control and experimental animals ( mg/100g wet. tissue) Groups Cholesterol Free fatty acids Triglycerides Phospholipids Normal 335.44 ± 18.90 606.10 ± 1.76 344.50 ± 23.20 1598.00 ± 19.30 Normal + Polyherbal formulation (200 mg/kg) 328.38 ± 5.74 601.93 ± 9.00 341.10 ± 21.00 1593.10 ± 24.10 Diabetic control 496.56 ± 13.10 921.60 ± 44.60 622.50 ± 18.80 1858.60 ± 18.70 Diabetic + Polyherbal formulation (200mg/kg) 398.65 ± 17.54 769.16 ± 3.30 456.25 ± 17.30 1718.80 ± 14.40 Diabetic + Tolbutamide (250 mg/kg) 405.21 ± 9.79 802.80 ± 3.77 530.80 ± 35.70 1769.30 ± 17.60 7 September 2011 14th ACC and ANRAP, Bangkok 15
  • 16. Groups Cholesterol Free fatty acids Triglycerides Phospholopids Normal + Polyherbal formulation (200 mg/kg) 372.08±8.28 432.51±1.60 278.75±14.60 1442.50±43.30 Diabetic control 546.90±23.80 743.00±5.70 501.10±34.10 2041.50±33.60 Diabetic+Polyher bal formulation (200 mg/kg) 435.20±12.18 556.80±8.50 382.90±9.28 1684.00±28.80 Diabetic+ Tolbutamide (250 mg/kg) 449.90±13.49 600.30±3.40 438.66±39.30 1819.30±34.70 7 September 2011 14th ACC and ANRAP, Bangkok 16 Table 5: Changes in levels of cholestrol, free fatty acids, triglycerides and phospholipids in kidney of control and experimental animals ( mg/100g wet. tissue)
  • 17. Conclusion • Polyherbal formulation of Annona squamosa and Nigella sativa, exert a significant antihyperlipidemic. This could be due to combined effect of Annona squamosa and Nigella sativa. Hence the antihyperlipidemic effect of polyherbal formulation of Annona squamosa and Nigella sativa in particular could be considered as of possible therapeutic value 7 September 2011 14th ACC and ANRAP, Bangkok 17
  • 18. Liposomes 7 September 2011 14th ACC and ANRAP, Bangkok 18 – Spherical vesicles with a phospholipid bilayer Hydrophilic HydrophobicHydrophobic
  • 19. 7 September 2011 14th ACC and ANRAP, Bangkok 19
  • 20. Liposome Preparation 7 September 2011 14th ACC and ANRAP, Bangkok 20
  • 21. Liposome Preparation 7 September 2011 14th ACC and ANRAP, Bangkok 21
  • 22. Liposome Preparation 7 September 2011 14th ACC and ANRAP, Bangkok 22
  • 23. Lipid Peroxidation • Most phospholipid liposomes contain unsaturated acyl chains as part of their molecular structure and susceptible to oxidative degradation. It can be minimized by the use of animal derived lipids like egg PC, which has less saturated lipids, use of light resistant containers, use of antioxidants are useful in minimizing oxidation. 7 September 2011 14th ACC and ANRAP, Bangkok 23
  • 24. Diabetic Current Research • Mangifera indica(stem,fruits,etc) – Anacardiaceae – Mango • Gossypiumherbaceum(flowers,etc ) – Malvaceae – Cotton • Cocos nucifera(roots,etc) – Arecaceae – Coconut • Lawsonia inermis(bark,etc) – Lythraceae - Mendhi 7 September 2011 2414th ACC and ANRAP, Bangkok
  • 25. My Research Group 7 September 2011 14th ACC and ANRAP, Bangkok 25
  • 26. THANK YOUE-mail: bknanjwade@yahoo.co.in Cell No: 0091 9742431000 7 September 2011 14th ACC and ANRAP, Bangkok 26